Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix
โ Scribed by Claire F. Verschraegen; John J. Kavanagh; Evelyne Loyer; Diane Bodurka-Bevers; Andrzej P. Kudelka; Wei Hu; Monique Vincent; Tarra Nelson; Charles Levenback; Community Clinical Oncology Program
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 85 KB
- Volume
- 92
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
โฆ Synopsis
BACKGROUND.
The activity of the combination of carboplatin and liposomal doxorubicin was tested in a Phase II study of patients with recurrent cervical carcinoma.
METHODS. The combination of carboplatin (area under the concentration curve
[AUC], 5) and liposomal doxorubicin (Doxil; starting dose, 40 mg/m 2 ) was administered intravenously every 28 days to 37 patients with recurrent squamous cell cervical carcinoma to determine antitumor activity and toxicity profile.
๐ SIMILAR VOLUMES
## BACKGROUND. This study was conducted to determine the efficacy and safety of